Login / Signup

Minimal symptom expression achievement over time in generalized myasthenia gravis.

Akiyuki UzawaYukiko OzawaManato YasudaYosuke OnishiHiroyuki AkamineSatoshi Kuwabara
Published in: Acta neurologica Belgica (2023)
From the early phases of immunotherapy, MSE is a good marker of therapeutic goal in patients with generalized MG.
Keyphrases
  • myasthenia gravis
  • poor prognosis
  • binding protein
  • patient reported